148 related articles for article (PubMed ID: 37008392)
1. Cystoid Macular Edema Arising 10 Years After Cessation of Pentosan Polysulfate Sodium Successfully Treated With Bevacizumab.
Szelog JT; Shah NS; Camejo MD
J Vitreoretin Dis; 2023; 7(1):83-86. PubMed ID: 37008392
[TBL] [Abstract][Full Text] [Related]
2. PENTOSAN POLYSULFATE SODIUM-INDUCED PIGMENTARY MACULOPATHY WITH NONLEAKING CYSTOID MACULAR EDEMA SUCCESSFULLY TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
De Larochellière E; Bourgault S
Retin Cases Brief Rep; 2022 Jul; 16(4):482-485. PubMed ID: 32541441
[TBL] [Abstract][Full Text] [Related]
3. Type 3 macular neovascularization in a patient with pentosan polysulfate maculopathy.
Bousquet E; Lee BA; Santina A; Sadda S; Sarraf D
Am J Ophthalmol Case Rep; 2023 Mar; 29():101771. PubMed ID: 36561881
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Pentosan Polysulfate Sodium Maculopathy Originally Diagnosed as Pattern Macular Dystrophy.
Case AW; Anderson MJ; Sayomac LE
Optom Vis Sci; 2021 Jun; 98(6):552-556. PubMed ID: 34039907
[TBL] [Abstract][Full Text] [Related]
5. Pentosan polysulfate maculopathy.
Lindeke-Myers A; Hanif AM; Jain N
Surv Ophthalmol; 2022; 67(1):83-96. PubMed ID: 34000253
[TBL] [Abstract][Full Text] [Related]
6. Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation.
Shah R; Simonett JM; Lyons RJ; Rao RC; Pennesi ME; Jain N
JAMA Ophthalmol; 2020 Aug; 138(8):894-900. PubMed ID: 32644147
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cystoid macular oedema secondary to pentosan polysulfate maculopathy using anti-VEGF and intravitreal steroid injections.
De Silva SR; De Silva I; Pal B
Eur J Ophthalmol; 2021 Dec; ():11206721211066387. PubMed ID: 34866437
[TBL] [Abstract][Full Text] [Related]
8. VISUAL AND ANATOMICAL CHANGES AFTER DRUG CESSATION IN PENTOSAN POLYSULFATE SODIUM-ASSOCIATED MACULOPATHY.
Gupta PR; Grewal DS
Retin Cases Brief Rep; 2023 Sep; 17(5):507-510. PubMed ID: 37643033
[TBL] [Abstract][Full Text] [Related]
9. POTENTIAL NEW-ONSET CLINICALLY DETECTABLE PENTOSAN POLYSULFATE MACULOPATHY YEARS AFTER DRUG CESSATION.
Barnett JM; Jain N
Retin Cases Brief Rep; 2022 Nov; 16(6):724-726. PubMed ID: 33229920
[TBL] [Abstract][Full Text] [Related]
10. POSSIBLE EFFICACY OF TOPICAL DORZOLAMIDE IN THE TREATMENT OF PACLITAXEL-RELATED CYSTOID MACULAR EDEMA.
Dwivedi R; Tiroumal S
Retin Cases Brief Rep; 2018 Winter; 12(1):75-79. PubMed ID: 27749791
[TBL] [Abstract][Full Text] [Related]
11. RAPID PENTOSAN POLYSULFATE SODIUM MACULOPATHY PROGRESSION.
Somisetty S; Santina A; Abraham N; Lu A; Morales VR; Sarraf D
Retin Cases Brief Rep; 2023 Nov; 17(6):660-663. PubMed ID: 35385434
[TBL] [Abstract][Full Text] [Related]
12. Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study.
Jain N; Liao A; Garg SJ; Patel SN; Wykoff CC; Yu HJ; London NJS; Khurana RN; Zacks DN;
Ophthalmol Retina; 2022 Mar; 6(3):219-227. PubMed ID: 34298229
[TBL] [Abstract][Full Text] [Related]
13. Pentosan Polysulfate Maculopathy versus Inherited Macular Dystrophies: Comparative Assessment with Multimodal Imaging.
Barnes AC; Hanif AM; Jain N
Ophthalmol Retina; 2020 Dec; 4(12):1196-1201. PubMed ID: 32446908
[TBL] [Abstract][Full Text] [Related]
14. Maculopathy Secondary to Pentosan Polysulfate Use: A Single-Center Experience.
Kalbag NS; Maganti N; Lyon AT; Mirza RG
Clin Ophthalmol; 2021; 15():513-519. PubMed ID: 33603329
[TBL] [Abstract][Full Text] [Related]
15. Nationwide Usage of Pentosan Polysulfate and Practice Patterns of Pentosan Polysulfate Maculopathy Screening in South Korea.
Kim J; Kwon HY; Kim JH; Ahn SJ
Ophthalmol Retina; 2024 Mar; 8(3):246-253. PubMed ID: 37832716
[TBL] [Abstract][Full Text] [Related]
16. Macular Hole in a patient with Pentosan Polysulfate Maculopathy.
Arora N; Hoyek S; Patel NA
Retin Cases Brief Rep; 2023 Jun; ():. PubMed ID: 37321232
[TBL] [Abstract][Full Text] [Related]
17. An unusual case of rapid resolution of bilateral vitelliform deposits after discontinuation of pentosan polysulfate sodium.
Kalaw FGP; Scott NL; Borooah S
Am J Ophthalmol Case Rep; 2023 Dec; 32():101875. PubMed ID: 37645698
[TBL] [Abstract][Full Text] [Related]
18. Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States.
Ludwig CA; Vail D; Callaway NF; Pasricha MV; Moshfeghi DM
Ophthalmology; 2020 Apr; 127(4):535-543. PubMed ID: 31899034
[TBL] [Abstract][Full Text] [Related]
19. Age-Related Macular Degeneration Masquerade: A Review of Pentosan Polysulfate Maculopathy and Implications for Clinical Practice.
Mukhopadhyay C; Boyce TM; Gehrs KM; Folk JC; Mullins RF; Luo Y; Kreder K; Sohn EH
Asia Pac J Ophthalmol (Phila); 2022 Mar-Apr 01; 11(2):100-110. PubMed ID: 35533330
[TBL] [Abstract][Full Text] [Related]
20. Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort.
Jain N; Li AL; Yu Y; VanderBeek BL
Br J Ophthalmol; 2020 Aug; 104(8):1093-1097. PubMed ID: 31694837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
